OCT market to hit $800 million by 2012

Article

By 2012 the market for optical coherence tomography (OCT) is predicted to hit the $800 million mark.

By 2012 the market for optical coherence tomography (OCT) is predicted to hit the $800 million mark, according to a recent market research report.

The report, "Optical Coherence Tomography - Technology, markets and applications: 2008-2021", from the publishers of BioOptics World quantifies this rapidly growing market for the first time. Currently the global market for OCT systems is around $200 million and is growing at an annual rate of 34%.

It is expected that the first commercial application of OCT, ophthalmology, will remain the dominant application until 2012, however, new applications and products are beginning to emerge in cardiology, dentistry, cancer detection, glucose monitoring and dermatology. In particular, commercial activity for OCT in intravascular imaging has been gaining momentum over the past 12 months.

Much of this recent activity in the market is being driven by a shift from time-domain to Fourier-domain OCT. While similar, Fourier-domain systems offer twice the resolution and 50 to 100 times the image-acquisition speed. Furthermore, because the Fourier-domain technique is not protected under tightly held patents, more companies are able to develop or market products using the technology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.